Previous 10 | Next 10 |
home / stock / insm / insm articles
Insmed (NASDAQ:INSM) has outperformed the market over the past 10 years by 4.66% on an annualized basis producing an average annual return of 15.55...
These ten large-cap stocks were the best performers in the last week. Are they in your portfolio? Rivian Automotive Inc (NASDAQ:RIVN) stock gained...
Insmed (NASDAQ:INSM) has outperformed the market over the past 10 years by 4.84% on an annualized basis producing an average annual return of 15.98...
U.S. stocks were mixed, with the Dow Jones index falling around 90 points on Friday. Shares of Macy’s, Inc. (NYSE:M) rose sharply during Frid...
U.S. stocks were mixed, with the Dow Jones index falling around 200 points on Thursday. Shares of Tesla Inc (NASDAQ:TSLA) rose sharply during Thurs...
As of June 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in th...
U.S. stocks were lower, with the Dow Jones index falling around 1% on Thursday. Shares of HP Inc. (NYSE:HPQ) rose sharply during Thursday's se...
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 250 points on Tuesday. The Dow traded down 0.69% to ...
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 100 points on Tuesday. The Dow traded down 0.36% to 38,...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 08:00:06 ET Vamil Divan from Guggenheim issued a price target of $95.00 for INSM on 2024-07-09 06:44:00. The adjusted price target was set to $95.00. At the time of the announcement, INSM was trading at $70.05. The overall price target consensus is at $72.91 w...
Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference PR Newswire —New Graph Depicting 52-Week FEV1 Data Illustrate Significantly Less Decline in Lung Function for Bren...